Nothing Special   »   [go: up one dir, main page]

HRP970270B1 - Antifungal compositions with improved bioavailability - Google Patents

Antifungal compositions with improved bioavailability

Info

Publication number
HRP970270B1
HRP970270B1 HR970270A HRP970270A HRP970270B1 HR P970270 B1 HRP970270 B1 HR P970270B1 HR 970270 A HR970270 A HR 970270A HR P970270 A HRP970270 A HR P970270A HR P970270 B1 HRP970270 B1 HR P970270B1
Authority
HR
Croatia
Prior art keywords
improved bioavailability
antifungal compositions
antifungal
compositions
bioavailability
Prior art date
Application number
HR970270A
Other languages
English (en)
Inventor
Elvire Colette Baert Lieven
Verreck Geert
Thone Dany
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26142825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP970270(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP970270A2 publication Critical patent/HRP970270A2/xx
Publication of HRP970270B1 publication Critical patent/HRP970270B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR970270A 1996-05-20 1997-05-20 Antifungal compositions with improved bioavailability HRP970270B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201430 1996-05-20
EP97200698 1997-03-07

Publications (2)

Publication Number Publication Date
HRP970270A2 HRP970270A2 (en) 1998-04-30
HRP970270B1 true HRP970270B1 (en) 2005-02-28

Family

ID=26142825

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970270A HRP970270B1 (en) 1996-05-20 1997-05-20 Antifungal compositions with improved bioavailability

Country Status (34)

Country Link
US (4) US6509038B2 (pt)
EP (1) EP0904060B1 (pt)
JP (1) JP3391801B2 (pt)
KR (1) KR19990044257A (pt)
CN (1) CN1165291C (pt)
AR (1) AR007195A1 (pt)
AT (1) ATE255883T1 (pt)
AU (1) AU722101B2 (pt)
BG (1) BG64368B1 (pt)
BR (1) BR9706897B1 (pt)
CA (1) CA2240161C (pt)
CY (1) CY2434B1 (pt)
CZ (1) CZ293841B6 (pt)
DE (1) DE69726729T2 (pt)
DK (1) DK0904060T3 (pt)
EA (1) EA001219B1 (pt)
EE (1) EE03902B1 (pt)
ES (1) ES2212810T3 (pt)
HK (1) HK1018002A1 (pt)
HR (1) HRP970270B1 (pt)
HU (1) HU227745B1 (pt)
ID (1) ID16926A (pt)
IL (1) IL124935A (pt)
MX (1) MX9805418A (pt)
MY (1) MY123827A (pt)
NO (1) NO320495B1 (pt)
NZ (1) NZ330739A (pt)
PL (1) PL188566B1 (pt)
PT (1) PT904060E (pt)
SI (1) SI0904060T1 (pt)
SK (1) SK284145B6 (pt)
TR (1) TR199801225T2 (pt)
TW (1) TW460282B (pt)
WO (1) WO1997044014A1 (pt)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
KR100288890B1 (ko) * 1997-12-31 2001-05-02 최현식 이트라코나졸 경구용 제제 및 그의 제조방법
AU1511399A (en) * 1997-12-31 1999-07-19 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
KR100514330B1 (ko) * 1997-12-31 2006-02-17 주식회사 중외제약 난용성 약물을 함유하는 코팅정
ES2157731B1 (es) * 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
IL145140A0 (en) * 1999-03-24 2002-06-30 Fmc Corp Improved aqueous solubility pharmaceutical formulations
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
JP5767429B2 (ja) 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
EP1239831B1 (en) * 1999-12-23 2012-10-31 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
MXPA02012683A (es) * 2000-06-22 2003-04-25 Novartis Ag Composiciones farmaceuticas solidas de valsartan.
DE10038571A1 (de) * 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
DE60215623T2 (de) 2001-02-14 2007-08-30 Tibotec Pharmaceuticals Ltd. Breitspektrum 2-(substituierte-amino)-benzothiazol-sulfonamide hiv protease inhibitoren
IL158092A0 (en) 2001-04-09 2004-03-28 Tibotec Pharm Ltd Broadspectrum 2- (substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
MXPA03010258A (es) 2001-05-11 2005-03-07 Tibotec Pharm Ltd 2-amino-benzoxazol sulfonamidas, inhibidores de amplio espectro de la vih proteasa.
AU2002317063A (en) * 2001-06-12 2002-12-23 Smartrix Technologies Inc Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
PT1404300E (pt) 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
KR100455216B1 (ko) * 2001-06-27 2004-11-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법
US7163700B2 (en) * 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
IL160570A0 (en) 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
UA79248C2 (en) 2001-11-09 2007-06-11 Janssen Pharmaceutica Nv Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US7763641B2 (en) 2001-12-21 2010-07-27 Tibotec Pharmaceuticals Ltd. Broadspectrum heterocyclic substituted phenyl containing sulfonamide HIV protease inhibitors
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
CN1630629B (zh) 2002-02-28 2010-05-05 日本烟草产业株式会社 酯化合物及其医药用途
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
AR039887A1 (es) 2002-05-17 2005-03-09 Tibotec Pharm Ltd Inhibidores de la proteasa de hiv de benzisoxazol sulfonamida sustituida de amplio espectro, composiciones y combinaciones farmaceuticas, y uso de dichos inhibidores para la elaboracion de un medicamento para tratar condiciones asociadas con hiv y otros retrovirus patogenos
EP1521571A1 (en) * 2002-07-04 2005-04-13 Janssen Pharmaceutica N.V. Solid dispersion comprising two different polymer matrixes
EP1546153A1 (en) 2002-08-14 2005-06-29 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors
EP2422773A3 (en) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
EP1438961B2 (en) * 2003-01-14 2014-08-20 Acino Pharma AG Bioequivalent composition of itraconazole dispersed in a hydrophilic polymer
EP1594468A2 (en) * 2003-02-03 2005-11-16 Novartis AG Process for preparing a solid dispersion pharmaceutical product
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
US20060172010A1 (en) * 2003-07-17 2006-08-03 Gael Lamoureux Process for preparing particles containing an antiviral
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP4832897B2 (ja) 2003-08-29 2011-12-07 日本たばこ産業株式会社 エステル誘導体及びその医薬用途
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
SG145742A1 (en) 2003-09-11 2008-09-29 Tibotec Pharm Ltd Entry inhibitors of the hiv virus
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
AU2005219443A1 (en) * 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
AR048650A1 (es) 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
JP5073480B2 (ja) 2004-05-07 2012-11-14 セコイア、ファーマシューティカルズ、インコーポレイテッド 耐性防止レトロウイルスプロテアーゼ阻害薬
EP1751156B1 (en) 2004-05-17 2010-09-15 Tibotec Pharmaceuticals 6,7,8,9-substituted 1-phenyl-1,5-dihydro-pyrido(3,2-b)indol-2-ones useful as anti-infective pharmaceutical agents
BRPI0511267A (pt) 2004-05-17 2007-11-27 Tibotec Pharm Ltd 1,5-diidropirido[3,2-b]indol-2-onas 4-substituìdas
JP4898668B2 (ja) 2004-05-17 2012-03-21 テイボテク・フアーマシユーチカルズ・リミテツド １−ヘテロシクリル−１，５−ジヒドロ−ピリド［３，２−ｂ］インドール−２−オン
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
KR20050119397A (ko) * 2004-06-16 2005-12-21 보람제약주식회사 고상용해를 이용한 난용성 약물의 가용화 방법과 이를이용한 가용화 조성물
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
KR100708974B1 (ko) * 2004-07-19 2007-04-18 주식회사종근당 수용성 수지를 이용한 이트라코나졸 고체분산체
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2006026504A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Mucoadhesive oral formulations of high permeability, high solubility drugs
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
CA2582767C (en) * 2004-10-25 2011-05-24 Japan Tobacco Inc. Solid formulation with improved solubility and stability and method for producing said formulation
CA2598204C (en) * 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
JP5096927B2 (ja) * 2004-12-31 2012-12-12 レディ ユーエス セラピューティックス， インコーポレイテッド Ｃｅｔｐインヒビターとしての新規ベンジルアミン誘導体
AR056652A1 (es) 2005-04-11 2007-10-17 Tibotec Pharm Ltd Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
JP2009504590A (ja) 2005-08-08 2009-02-05 アボット ゲーエムベーハー ウント コンパニー カーゲー 改善された生物学的利用能をもつ剤型
CA2618255C (en) * 2005-08-08 2015-05-26 Abbott Gmbh & Co. Kg Itraconazole compositions with improved bioavailability
JP5435946B2 (ja) * 2005-08-22 2014-03-05 ジョンズ ホプキンス ユニバーシティ 疾患を処置するためのヘッジホッグ経路アンタゴニスト
US7476405B2 (en) * 2006-02-23 2009-01-13 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
CA2646090A1 (en) 2006-04-03 2007-10-11 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 3,4-dihydro-imidazo[4,5-b]pyridin-5-ones
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
HUE031590T2 (en) 2006-06-19 2017-07-28 Alpharma Pharmaceuticals Llc Pharmaceutical preparations
US20100003332A1 (en) * 2006-07-27 2010-01-07 Amorepacific Corporation Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug
EP2073797A2 (en) * 2006-10-11 2009-07-01 Alpharma, Inc. Pharmaceutical compositions
EP2155166A2 (en) * 2007-05-11 2010-02-24 F. Hoffmann-Roche AG Pharmaceutical compositions for poorly soluble drugs
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
CN101835492B (zh) 2007-08-21 2012-11-21 德克萨斯州立大学董事会 用于制药应用的热动力学混合
EP2471515A3 (en) 2007-09-14 2012-12-26 Wockhardt Limited Rhein or diacerein compositions
CA2709236A1 (en) 2007-09-27 2009-04-02 Wockhardt Research Centre Pharmaceutical compositions of rhein or diacerein
US20090130160A1 (en) * 2007-11-21 2009-05-21 Fiber Innovation Technology, Inc. Fiber for wound dressing
AU2008329677B2 (en) 2007-11-28 2015-02-19 Sequoia Pharmaceuticals, Inc. Compositions and methods for inhibiting cytochrome P450 2D6
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2009079521A1 (en) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
CA2712010A1 (en) * 2008-01-11 2009-07-12 Cipla Limited Solid pharmaceutical dosage form
EP2257160B1 (en) 2008-02-21 2017-07-05 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome p450
CA2720108C (en) 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
JP2011516612A (ja) * 2008-04-15 2011-05-26 シェーリング コーポレイション 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
EA013132B1 (ru) * 2008-12-31 2010-02-26 Открытое Акционерное Общество "Верофарм" Противогрибковое средство для вагинального применения
CN101780046B (zh) * 2009-01-16 2011-09-21 北京化工大学 一种伊曲康唑复合粉体及其制备方法
JP5714600B2 (ja) 2009-12-18 2015-05-07 フリースランドカンピナ・ネーデルランド・ホールディング・ビー．ブイ．ＦｒｉｅｓｌａｎｄＣａｍｐｉｎａ Ｎｅｄｅｒｌａｎｄ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 共加工された錠用賦形剤混合物、その調製及び使用
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
ES2511145T3 (es) * 2010-10-14 2014-10-22 Abbott Gmbh & Co. Kg Formulación de dispersión sólida de curcuminoides
CN102068416A (zh) * 2010-12-30 2011-05-25 安徽先求药业有限公司 一种含有伊曲康唑的口服固体制剂及其制备方法
CN103391769A (zh) 2011-02-17 2013-11-13 霍夫曼-拉罗奇有限公司 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
EP2744481A4 (en) * 2011-08-16 2015-07-01 Merck Sharp & Dohme USE OF INORGANIC MATRIX AND COMBINATIONS OF ORGANIC POLYMERS FOR THE PREPARATION OF STABLE AMORPHOUS DISPERSIONS
CN103827105B (zh) 2011-08-18 2016-08-17 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(cetp)抑制剂的取代的杂环胺化合物
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
EP2760864B1 (en) 2011-09-27 2018-01-24 Dr. Reddy's Laboratories Ltd. 5-BENZYLAMINOMETHYL-6-AMINOPYRAZOLO[3,4-b]PYRIDINE DERIVATIVES AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
MX366829B (es) 2012-06-21 2019-07-25 Mayne Pharma Int Pty Ltd Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
EP2874607B1 (en) * 2012-07-17 2017-05-31 Dow Global Technologies LLC Solid dispersion comprising a highly substituted hydroxyalkyl methylcellulose
JP2016503420A (ja) 2012-11-19 2016-02-04 ドクター レディズ ラボラトリーズ リミテッド Ｃｅｔｐ阻害剤の薬学的組成物
UA116004C2 (uk) 2013-01-22 2018-01-25 Ф. Хоффманн-Ля Рош Аг Фармацевтична композиція з покращеною біодоступністю
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
US10259921B2 (en) * 2014-01-16 2019-04-16 Dow Global Technologies Llc Support materials for 3D printing
WO2016200673A1 (en) * 2015-06-09 2016-12-15 Dow Global Technologies Llc Support materials for 3d printing
US20200009060A1 (en) * 2016-05-09 2020-01-09 Dispersol Technologies, Llc Improved drug formulations
EP3675832A1 (en) 2017-09-01 2020-07-08 Jordan Sweden Medical and Sterilization Company Fast self dispersible dosage forms of deferasirox
CN109172532A (zh) * 2018-10-24 2019-01-11 北京哈三联科技有限责任公司 一种伊曲康唑分散片及其制备方法和应用
MX2022002280A (es) * 2019-08-28 2022-04-25 Lubrizol Advanced Mat Inc Dispersiones solidas amorfas de farmaco-polimero usando polimeros de poli(acido acrilico) lineales.
KR102266145B1 (ko) * 2019-09-26 2021-06-17 대봉엘에스 주식회사 비정질 에피나코나졸 고체 분산체
WO2023025672A1 (en) 2021-08-25 2023-03-02 Basf Se Direct tableting auxiliary composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
ATE5852T1 (de) * 1978-11-20 1984-02-15 American Home Products Corporation Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung.
JPS5879915A (ja) * 1981-11-09 1983-05-13 Nippon Soda Co Ltd 棒状薬剤の製造方法
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US5028433A (en) 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
JPH0667840B2 (ja) * 1988-11-30 1994-08-31 萬有製薬株式会社 Ｎｂ―８１８の易吸収性製剤
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
CA2108575C (en) * 1991-04-16 2002-10-22 Kouichi Nakamichi Method of manufacturing solid dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
PL172358B1 (en) * 1992-03-18 1997-09-30 Janssen Pharmaceutica Nv Stereoisomeric form of itraconazole or saperconazole and method of obtaining same
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
JP3413238B2 (ja) 1993-03-31 2003-06-03 オリンパス光学工業株式会社 位相制御膜構造体
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
JP2948111B2 (ja) * 1994-09-16 1999-09-13 塩野義製薬株式会社 経口投与用油性組成物

Also Published As

Publication number Publication date
PL330931A1 (en) 1999-06-07
EP0904060B1 (en) 2003-12-10
KR19990044257A (ko) 1999-06-25
EP0904060A1 (en) 1999-03-31
US7081255B2 (en) 2006-07-25
ES2212810T3 (es) 2004-08-01
NO982599L (no) 1998-11-19
US8591948B2 (en) 2013-11-26
EA199800571A1 (ru) 1998-12-24
CA2240161A1 (en) 1997-11-27
US20060263436A1 (en) 2006-11-23
US6509038B2 (en) 2003-01-21
JPH11509238A (ja) 1999-08-17
CZ293841B6 (cs) 2004-08-18
CZ188598A3 (cs) 1998-11-11
IL124935A (en) 2001-06-14
NO982599D0 (no) 1998-06-05
MX9805418A (es) 1998-10-31
CA2240161C (en) 2005-05-24
SK284145B6 (sk) 2004-10-05
NO320495B1 (no) 2005-12-12
DK0904060T3 (da) 2004-04-13
US20030082239A1 (en) 2003-05-01
AU2956297A (en) 1997-12-09
US20140134244A1 (en) 2014-05-15
CY2434B1 (en) 2004-11-12
HU227745B1 (en) 2012-02-28
DE69726729D1 (de) 2004-01-22
WO1997044014A1 (en) 1997-11-27
NZ330739A (en) 1999-06-29
SK84898A3 (en) 1999-03-12
BR9706897B1 (pt) 2010-09-21
US9642806B2 (en) 2017-05-09
EE9800304A (et) 1999-02-15
HUP9901620A2 (hu) 1999-10-28
US20010007678A1 (en) 2001-07-12
SI0904060T1 (en) 2004-04-30
HK1018002A1 (en) 1999-12-10
HRP970270A2 (en) 1998-04-30
MY123827A (en) 2006-06-30
PL188566B1 (pl) 2005-02-28
PT904060E (pt) 2004-04-30
EA001219B1 (ru) 2000-12-25
DE69726729T2 (de) 2004-12-02
CN1165291C (zh) 2004-09-08
BR9706897A (pt) 1999-08-31
HUP9901620A3 (en) 2000-03-28
AU722101B2 (en) 2000-07-20
ATE255883T1 (de) 2003-12-15
BG64368B1 (bg) 2004-12-30
CN1209740A (zh) 1999-03-03
TR199801225T2 (xx) 1998-11-23
ID16926A (id) 1997-11-20
BG102532A (en) 1999-02-26
AR007195A1 (es) 1999-10-13
IL124935A0 (en) 1999-01-26
JP3391801B2 (ja) 2003-03-31
TW460282B (en) 2001-10-21
EE03902B1 (et) 2002-12-16

Similar Documents

Publication Publication Date Title
IL124935A0 (en) Antifungal compositions with improved bioavailability
ZA973344B (en) Antifungal compositions.
HUP9903388A3 (en) Fungicidal composition
HK1017855A1 (en) Antifungal composition with enhanced bioavailability
IL123715A0 (en) Antifungal compositions
HU9700533D0 (en) Microbicidal composition
AU1598399A (en) Injectable antifungal formulations
GB9714461D0 (en) Antifungal agent
GB9818258D0 (en) Antifungal compositions
PL318520A1 (en) Herbicidal composition
GB2329418B (en) Stays
GB2331123B (en) Stays
ZA974338B (en) Anitfungal compositions with improved bioavailability
AU9464398A (en) Novel antifungal compounds
ZA987526B (en) Fungicidal compositions
GB9720096D0 (en) Stays
GB9611006D0 (en) Antifungal compositions
GB9619534D0 (en) Fungicidal composition
GB9603722D0 (en) Antifungal
GB9615091D0 (en) Herbicidal composition
GB2330622B (en) Stays
GB9604147D0 (en) Antifungal agents
GB9606552D0 (en) Antifungal proteins
GB9722452D0 (en) Stays
GB9608063D0 (en) Biocidal composition

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20160412

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20170520